Digital Health February 9, 2023
Macmillan Cancer Support has invested in Neutrocheck, a portable device and app being developed by 52 North Health, to help people with cancer test for neutropenic sepsis from their own homes.
Neutrocheck’s device is centred around an at-home finger prick test that could detect the life-threatening reaction to an infection. This could prove vital for patients undergoing chemotherapy who may be immune suppressed, making them more likely to develop neutropenic sepsis.
Currently, if they sent to A&E, they are given appropriate antibiotics as a precaution and undergo a full blood test.
With the test, patients can check their risk at home, allowing them to take informed and immediate steps to seek care and be prioritised at hospitals. It also helps...
Today's Sponsors
Today's Sponsor